Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma -- With Much Faster Treatment Time
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park Comprehensive Cancer Center today at the 2024... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news
First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive Result
(MedPage Today) -- SAN FRANCISCO -- Almost half of patients with untreated cisplatin-ineligible advanced urothelial carcinoma responded to the combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx), but that result fell short of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
Why Is HOOKIPA Pharma Stock Trading Lower Today?
HOOKIPA Pharma Inc HOOK will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 program in human papillomavirus 16 positive (HPV16+) head and neck squamous cell carcinoma (HNSCC) and its two Gilead Science Inc GILD-partnered infectious disease cure…#hookipapharmainchook #gileadscienceinc #hookipa #rocheholdingsag #rhhby #kras #gileadsciences #gilead (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2024 Category: Consumer Health News Source Type: news
The cancers that doctors don't want to call cancers... because the word is 'too scary'
Low-grade prostate cancers that grow very slowly should not be called cancer or carcinoma, doctors have suggested. It can scare men and even their doctors into more aggressive treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - January 29, 2024 Category: Consumer Health News Source Type: news
Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer
MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2024 Category: Pharmaceuticals Source Type: news
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings.
Patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
Adjuvant Pembrolizumab Boosts DFS in High-Risk Muscle Invasive Urothelial Cancer
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) more than doubled disease-free survival (DFS) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to the AMBASSADOR trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 28, 2024 Category: Hematology Source Type: news
FAPI-PET shows promise in head and neck cancer patients
In this study, the researchers tested the approach for the first time in head and neck cancer patients with tumors of unknown origin in a prospective clinical trial.PET/CT and MR images of a 72-year-old woman. (A) F-18 FDG-PET images (left and top) and PET/CT images (bottom) shown in coronal, sagittal, and axial views (from left to right), demonstrated a metastatic lymph node of the right neck with intensive metabolic activity (black arrow, SUVmax, 30.1) but presented no evidence for primary tumor. (B) Ga-68 FAPI-PET images (top and right) and PET/CT images (bottom), shown in axial, sagittal, and coronal views (from left t...
Source: AuntMinnie.com Headlines - January 26, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Radiation Oncology/Therapy Source Type: news
Invasive Breast Cancer, Breast Cancer Mortality Increased Long Term After DCIS
THURSDAY, Jan. 25, 2024 -- Women with non-screen-detected ductal carcinoma in situ have an increased risk for invasive breast cancer and breast cancer death, according to a study published online Jan. 24 in The BMJ.
Gurdeep S. Mannu, M.B.B.S.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 25, 2024 Category: Pharmaceuticals Source Type: news
New Standard for Unresectable Hepatocellular Carcinoma?
(MedPage Today) -- SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.
Patients who received durvalumab... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 21, 2024 Category: Gastroenterology Source Type: news
FDA approves erdafitinib for locally advanced or metastatic urothelial carcinoma
On January 19, 2024, the Food and Drug Administration approved erdafitinib (Balversa, Janssen Biotech) for locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
U.S. Food and Drug Administration Grants Full Approval for Balversa to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations
Balversa® is the First and Only Targeted Therapy for Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Susceptible Fibroblast Growth Factor Receptor Alterations
Phase 3 THOR Study Showed a 36 Percent Reduction in the Risk... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 19, 2024 Category: Drugs & Pharmacology Source Type: news
Patient adherence to ultrasound liver cancer surveillance recs is low
Patient adherence to ultrasound hepatocellular carcinoma (HCC) surveillance imaging recommendations has been suboptimal, according to research published January 12 in Radiology: Imaging Cancer.Ultrasound is considered a cost-effective surveillance method in the management of HCC, a common type of liver cancer associated with long-term liver damage and scarring of the liver and chronic infections such as hepatitis B and hepatitis C, a research team from the University of California, San Francisco (UCSF) noted. But whether patients comply with surveillance recommendations prompted by the ultrasound LI-RADS metric isn't cle...
Source: AuntMinnie.com Headlines - January 16, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news
